UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June ~~March 5~~14, 2017

(Exact name of registrant as specified in its charter)

Wyoming		333-177122		46-0525223
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3651 Lindell Rd. Suite D155

Las Vegas, NV 89103

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: 702-943-0309

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~This 1Current Report on Form 8-K includes certain statements that are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.01 ~~Entry~~Any ~~into~~statement ~~Material~~in ~~Definitive~~this ~~Agreement~~report that is not a statement of historical fact may be deemed to be a forward-looking statement. We often use these types of statements when discussing our plans and strategies, our anticipation of revenues from designated markets and statements regarding the development of our businesses, the markets for our services and products, our anticipated capital expenditures, operations, support systems, changes in regulatory requirements and other statements contained in this report regarding matters that are not historical facts. When used in this report, the words “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate” and other similar expressions are generally intended to identify forward-looking statements. Because these forward-looking statements involve risks and uncertainties, actual results may differ materially from those expressed or implied by these forward-looking statements. There can be no assurance that: (i) we have correctly measured or identified all of the factors affecting us or the extent of their likely impact; (ii) the publicly available information with respect to these factors on which our analysis is based is complete or accurate; (iii) our analysis is correct; or (iv) our strategy, which is based in part on this analysis, will be successful. We do not assume any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

~~License~~Item 1.02 Termination of a Material Definitive Agreement

On ~~March~~June 514, 2017, Health Advance Inc. (the “Company”) ~~entered~~sent ~~into~~written anotice ~~license~~to ~~agreement (the “License Agreement”) with~~ Micro Medtech, Ltd., a foreign limited liability company held in Federated States of Micronesia, existing ~~under~~as a foreign corporation in the ~~laws~~State of Colorado, United States (“MMT”) to terminate the license agreement dated February 28, 2017 and entered into on March 5, 2017 (the “License Agreement”) to acquire exclusive licensing rights in North America to cebidiofen and polyoxyfen, two patent-pending, product formulations for pharmaceutical foods made from ibuprofen and botanical extract blends containing cannabidiol, mitragyna speciose, and kava.; Pursuant to the terms of the License Agreement, the License Agreement may be cancelled by providing ninety (90) days written notice to MMT. Accordingly, the License Agreement shall terminate on September 12, 2017.

~~The~~Item ~~Company~~4.02 ~~agrees to issue Forty~~Non-~~Million common~~Reliance ~~shares~~ of ~~the~~Previously ~~Company~~Issued asFinancial ~~outstanding~~Statements ~~payment~~or ~~due to MMT upon inception of License Agreement. In addition, the Company will issue to MMT Forty-Million warrant options for Forty-Million common shares of the Company at~~ a ~~strike~~Related ~~price~~Audit ofReport ~~$0.07~~or ~~(USD)~~Completed ~~per share,~~Interim which are outstanding upon execution of the License Agreement on March 5, 2017. Furthermore, the License Agreement agrees to issue additional common shares of the Company, royalties, and stock options to MMT based performance and other related milestones.Review

~~The~~On ~~foregoing~~June ~~description~~14, of2017, a Quarterly Report on Form 10-Q for the ~~terms~~ period ended January 31, 2017 (the “June 14 10-Q”) was filed on behalf of the ~~License~~Company ~~Agreement~~with ~~are~~the ~~qualified~~signature inof ~~its~~Gregory ~~entirety~~Shusterman, byan ~~reference~~individual claiming to be Chairman of the ~~provisions~~Board of Directors of the ~~agreement~~Company. Mr. ~~filed~~Shusterman asis ~~Exhibit~~not an officer, director, or employee of the Company, does not have access to the Company’s internal financial statements, and had no authority or authorization to file the June 14 10-Q on behalf of the Company.1 Further, Mr. Shusterman did not consult with or receive approval or authorization from the Company’s independent auditor to file the June 14 10-Q. That same day, the Company was made aware of this ~~Current~~improper filing and is notifying shareholders and the public to not rely on the June 14 10-Q, which has incorrect information, financial statements and exhibits. The Company is still compiling the financial statements for the quarter ended January 31, 2017 and intends to file a Quarterly Report on Form 810-KQ ~~(this~~for ~~“Report”)~~the period ended January 31, ~~which~~2017 isonce ~~incorporated~~the byfinancial ~~reference~~statements ~~herein~~have been completed and the Company’s independent auditor has had a chance to review them.

~~Description of~~Item ~~Micro~~9.01 ~~Medtech,~~Financial ~~Ltd.~~Statement and Exhibits

~~Description~~(d) ~~of product formulations included in License Agreement are as follows:~~Exhibits

[a] USPTO Provisional Patent Pending No. 62364442 for "Cebidiofen", a product formulation for a medical food containing Ibuprofen and a unique botanical blend derived primarily from kava extract and cannabis extracts (known as cannabidiol or "CBD");

Exhibit No.	Description
99.1	Termination Letter from the Company to Micro Medtech, Ltd. dated June 14, 2017

[b] USPTO Provisional Patent Pending No. 62464423 for "Polyoxyfen", a product formulation a medical food containing Ibuprofen and a unique botanical blend derived primarily from kava and mitragyna speciose extracts;SIGNATURES

~~Beginning~~Pursuant ~~in March 2017 the Company and MMT will begin working together with health claim experts Nutrasource Diagnostics, Inc.~~ to ~~conduct a due diligence review and product development plan to determine claims and optimal commercialization strategies for cebidiofen and polyoxyfen. The formulas are specifically tied to~~ the ~~production~~requirements of the ~~neurotransmitters~~Securities ~~that~~Exchange ~~enable~~Act ~~management~~of ~~and enhancement to sensory response to pain and inflammation~~1934, ~~formulated by ingredients that are classified as Generally Recognized as Safe (GRAS) by~~ the ~~FDA.~~registrant ~~The~~has ~~Product Development~~duly ~~Plan~~caused ~~process~~this ~~for~~report ~~both (provisional) patent-pending product formulations will take six~~ to ~~eight~~be ~~weeks~~signed toon ~~complete~~its ~~from the~~behalf ~~start~~by ~~date that will commence in March. The plans will identify current gaps in~~ the ~~research~~undersigned ~~and~~hereunto ~~outline~~duly ~~the clinical and regulatory pathways going forward~~authorized. Based upon the results of the plans for cebidiofen (primarily derived from cannabidiol fiber extract) and polyoxyfen (primarily derived from mitragyna speciose, also known as kratom), the requisite clinical studies and product testing will be conducted to meet the regulatory, clinical and manufacturing requirements for commercialization.

Item 3.02 Unregistered Sales of Equity Securities.

		Health Advance Inc.

Date: June 14, 2017		/s/ Jordan Starkman
		Jordan Starkman
		President, Chief Executive Officer, Chief Financial Officer, Chairman of the Board of Directors

Reference is made to the disclosure set forth under Items 1.01 of this Report, which disclosure is incorporated herein by reference.

The Company shall issue the Health Advance Shares in reliance upon the exemption from registration contained in Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”). Our reliance on Section 4(2) of the Securities Act was based upon the following factors: (a) the issuance of the securities was an isolated private transaction by us which did not involve a public offering; (b) there were only a limited number of offerees; (c) there were no subsequent or contemporaneous public offerings of the securities by us; (d) the securities were not broken down into smaller denominations; and (e) the negotiations for the sale of the stock took place directly between the offeree and us.

Item 8.01 Other Events.

On March 7, 2017, the Company issued a press release announcing the execution of the License Agreement with Micro Medtech, Ltd., a copy of which is attached as Exhibit 99.1 to this Report.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits:

Exhibit Number		Description
10.1		License Agreement, dated March 5, 2017, by and among Health Advance Inc., Micro Medtech, Ltd.
99.1		Press Release

FORWARD-LOOKING STATEMENTS :

Pursuant with the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, this Current Report on Form 8-K contains forward-looking statements about the Company's business affairs with Micro Medtech, Ltd. and affiliate partners for research and development, marketing, production, and sale of medical equipment and nutritional and pharmaceutics products, in additional to pertinent intellectual properties. These statements involve risks and uncertainties, and actual results may differ materially from the Company's expectations. The potential risks and uncertainties that could cause actual results to differ from the results predicted include, among others, whether the Company will be able to complete and fulfill actions specified within agreements with affiliated parties. Other risks and uncertainties that can affect the Company's performance are included under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Annual Report on Form 10-K for the year ended July 31, 2016 and the Quarterly Report on Form 10-Q for the quarter ended on October 31, 2016 which are on file with the Securities and Exchange Commission (SEC) and are available on the SEC’s website at www.sec.gov and on the Company websites (www.healthadvanceinc.com and www.hadvinc.com). All information provided in this Current Report on Form 8-K is as of March 7, 2017, and the Company undertakes no duty to update this information unless required by law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	HEALTH ADVANCE INC.
Date: March 7, 2017	By:	/s/ Jordan Starkman
		Jordan Starkman

Filing Compare · HEALTH ADVANCE INC.